A consensus statement from researchers on the proper use of Lu-177 PSMA-617 radionuclide therapy and patient selection is published.

Published Date: 06 Sep 2023

A new consensus statement from the Society of Nuclear Medicine and Molecular Imaging (SNMMI) offers standardized recommendations for the treatment of metastatic castrate-resistant prostate cancer (mCRPC).

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Can Alternating Venetoclax Regimens Improve AML Outcomes?

2.

Global inequalities found in cancer research funding

3.

A prostate cancer risk prediction algorithm could help target men at highest risk

4.

automated, precise reporting for clonality testing using NGS.

5.

PRO Data Strengthen Case for Dato-DXd in First-Line TNBC


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot